Locations
With its Head Office in Germany, Scope International is very well positioned within the largest pharmaceutical market and within one of the most important areas for clinical research in Western Europe.
Western Europe
Western European countries have decades of experience and many opinion leaders in Clinical Research. These countries could be extremely important as part of your Clinical Program in order to boost marketing after the launch of a new product.
Our Head Office is located in Mannheim, Germany, approximately 80 km from the Frankfurt Rhein Main Airport. From here we conduct clinical trials in
- Germany
- Austria
- Switzerland
- The Netherlands
Our regional offices are based in
- Paris, France
- Milano, Italy
- Barcelona, Spain (incl. CRAs in Portugal)
- London, UK
Eastern Europe
The Eastern Europe health care system is highly centralised. Large and homogenous patient populations are easily accessible and high recruitment rates can be achieved. Additionally, Eastern European countries are areas with a high number of treatment naive patients. All these countries, both EU and non EU members, have implemented the EU GCP directive in their national laws. Additionally, both investigators as well as patients are highly motivated in participating in clinical trials.
We have a well established regional presence in Eastern Europe with offices based in
- Zagreb, Croatia
- Prague, Czech Republic
- Rimavska Sobota, Slovakia
- Budapest, Hungary
- Vilnius, Lithuania (incl. CRAs in Estonia and Latvia)
- Krakow, Poland
- Bucharest, Romania (incl. CRAs in Moldavia)
- Moscow, Russia
- Belgrade, Serbia
- Sofia, Bulgaria
- Kiev, Ukraine
All offices were founded according to the local legislation and are owned by Scope International.
Scope International has extensive experience in conducting phase Ib – IV clinical studies in Europe covering a wide range of indications. We derive the utmost advantage from long-standing personal contacts for the conducting of trials in these countries.
Scope International currently employs 150 people throughout Europe.